ZIKA VIRUS TESTING GUIDANCE: SYMPTOMATIC NON-PREGNANT INDIVIDUALS WITH POSSIBLE ZIKA VIRUS EXPOSURE

Testing Recommendations for Healthcare Providers

Specimen collected < 14 days post-symptom onset

- Zika virus NAT testing
  - Positive Zika virus NAT
    - ACUTE ZIKA VIRUS INFECTION
  - Negative Zika virus NAT
    - Zika virus IgM serology
      - Non-negative Zika virus IgM
        - Plaque reduction neutralization test (PRNT)
          - Zika virus PRNT ≥ 10 AND Dengue virus PRNT < 10
          - ZIKA VIRUS INFECTION, TIMING OF INFECTION CANNOT BE DETERMINED
          - FUlavivirus infection, TIMING OF INFECTION CANNOT BE DETERMINED
          - Zika virus PRNT < 10
            - NO EVIDENCE OF ZIKA VIRUS INFECTION

Specimen collected ≥ 14 days post-symptom onset

- Negative Zika virus IgM

INTERPRETATION
Abbreviations: IgM = immunoglobulin M; NAT = nucleic acid test

1. NAT testing is not recommended for specimens obtained ≥ 14 days post-symptom onset.

2. Acceptable specimens for NAT testing include serum, or patient-matched serum and urine. Repeat NAT testing of a positive result is not indicated. Dengue and chikungunya virus NAT testing should be performed for patients at risk of exposure and with clinically compatible illness.

3. Dengue IgM serology should also be performed for patients at risk of exposure, and with clinically compatible illness.